Iovance Biotherapeutics (IOVA) Projected to Post Quarterly Earnings on Tuesday

Iovance Biotherapeutics (NASDAQ:IOVA) is expected to be releasing its Q4 2025 results before the market opens on Tuesday, February 24th. Analysts expect the company to announce earnings of ($0.22) per share and revenue of $81.6050 million for the quarter. Individuals can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Tuesday, February 24, 2026 at 8:30 AM ET.

Iovance Biotherapeutics Price Performance

Shares of NASDAQ:IOVA opened at $2.87 on Friday. Iovance Biotherapeutics has a 1 year low of $1.64 and a 1 year high of $6.09. The company has a market capitalization of $1.14 billion, a PE ratio of -2.39 and a beta of 0.76. The business has a fifty day moving average price of $2.59 and a two-hundred day moving average price of $2.39.

Institutional Trading of Iovance Biotherapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Granite Investment Partners LLC bought a new position in Iovance Biotherapeutics in the 4th quarter worth approximately $29,000. Motley Fool Asset Management LLC bought a new stake in Iovance Biotherapeutics during the 4th quarter valued at $29,000. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Iovance Biotherapeutics during the fourth quarter worth $46,000. HighTower Advisors LLC lifted its position in shares of Iovance Biotherapeutics by 67.9% during the fourth quarter. HighTower Advisors LLC now owns 19,089 shares of the biotechnology company’s stock worth $52,000 after acquiring an additional 7,718 shares in the last quarter. Finally, Diversify Wealth Management LLC bought a new position in shares of Iovance Biotherapeutics in the second quarter worth $34,000. Institutional investors own 77.03% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on IOVA shares. Barclays increased their price target on shares of Iovance Biotherapeutics from $9.00 to $10.00 and gave the company an “overweight” rating in a research report on Wednesday, December 17th. Chardan Capital dropped their target price on shares of Iovance Biotherapeutics from $20.00 to $17.00 and set a “buy” rating on the stock in a research note on Thursday, November 6th. The Goldman Sachs Group restated a “sell” rating and set a $2.00 price target on shares of Iovance Biotherapeutics in a research note on Thursday, February 5th. Finally, HC Wainwright lowered their price target on shares of Iovance Biotherapeutics from $20.00 to $9.00 and set a “buy” rating on the stock in a report on Wednesday, October 29th. Five analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Iovance Biotherapeutics has a consensus rating of “Hold” and an average price target of $10.50.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.

Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.